Trypanocidal drugs for chronic asymptomatic Trypanosoma cruzi infection

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 5, 2014, Pages

  Villar, Juan Carlos ^a   Perez, Juan Guillermo ^b   Cortes, Olga Lucia ^b   Riarte, Adelina ^c   Pepper, Micah ^d   Marin Neto, Jose Antonio ^e   Guyatt, Gordon H ^f  

^a UNIVERSIDAD AUTÓNOMA DE BUCARAMANGA   (Colombia)

^b FUNDACIÓN CARDIOINFANTIL INSTITUTO DE CARDIOLOGÍA   (Colombia)

^c Instituto Nacional de Diagnostico e Investigacion de la Enfermedad de Chagas Dr Mario Fatala Chaben   (Argentina)

^d BOSTON UNIVERSITY   (United States)

^e UNIVERSITY OF SÃO PAULO   (Brazil)

^f MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; ANTITRYPANOSOMAL AGENT; BENZNIDAZOLE; ITRACONAZOLE; NIFURTIMOX; PLACEBO;

ALL CAUSE MORTALITY; ANTIBODY TITER; ARTHRITIS; ASYMPTOMATIC INFECTION; CHAGAS DISEASE; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EDEMA; EYE REDNESS; FEVER; GASTROINTESTINAL SYMPTOM; HEADACHE; HEARTBURN; HOSPITALIZATION; HUMAN; INSOMNIA; LEUKOPENIA; LYMPHADENOPATHY; MALAISE; NEURITIS; PATIENT-REPORTED OUTCOME; PERIPHERAL NEUROPATHY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PRURITUS; RASH; REVIEW; SEROLOGY; SKIN MANIFESTATION; STOMACH PAIN; SYSTEMATIC REVIEW; TOXIC HEPATITIS; UNSPECIFIED SIDE EFFECT; VERTIGO; VOMITING; XENODIAGNOSIS; ANIMAL; CHAGAS CARDIOMYOPATHY; CHRONIC DISEASE; META ANALYSIS; OBSERVATIONAL STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); TRYPANOSOMA CRUZI;

ANIMALS; CHAGAS CARDIOMYOPATHY; CHAGAS DISEASE; CHRONIC DISEASE; HUMANS; OBSERVATIONAL STUDY AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TRYPANOCIDAL AGENTS; TRYPANOSOMA CRUZI;

EID: 84942793089     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD003463.pub2     Document Type: Review

References (112)

1. de Andrade ALS, De Oliveira RM, Almeida e Silva S, Luquetti A, Travassos LR, Almeida IC, et al.Randomised trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection. Lancet 1996;348:1407-13.
2. Andrade AL, Martelli C, Oliveira R, Silva S, Aires A, Soussumi L, et al.Short report: benznidazole efficacy among Trypanosoma cruzi-infected adolescents after a six-year follow-up. American Journal of Tropical Medicine and Hygiene 2004;71(5):594-7.
3. Apt W, Aguilera X, Arribada A, Pérez C, Miranda C, Sánchez G, et al.Treatment of chronic Chagas' disease with itraconazole and allopurinol. American Journal of Tropical Medicine and Hygiene 1998;59:133-8.
4. Britto C, Silveira C, Cardoso MA, Marques P, Luquetti A, Macêdo V, et al.Parasite persistence in treated chagasic patients revealed by xenodiagnosis and polymerase chain reaction. Memorias do Instituto Oswaldo Cruz 2001;96:1-4.
5. Catalioti F, Acquatella H. Mortality comparison of 5 years follow up in subjects with chronic Chagas disease with and without benznidazol treatment [Comparación de mortalidad durante seguimiento por 5 años en sujetos con enfermedad de Chagas crónica con y sin tratamiento de benznidazol]. Revista de Biología Tropical 1998;27(Suppl):29-31.
6. Coura Rodrigues J, De Abreu LL, Faraco Wilcox HP, Petana W. Comparative controlled study using benznidazole, nifutimox and placebo in chronic Chagas' disease in field areas with interrupted transmission. I. Preliminary Evaluation [Estudo comparativo controlado com emprego de Benznidazole, nifurtimox e placebo, na forma cronica da doenca de Chagas, em uma area de campo com transmissao interrompida. I. Avialação Preliminar]. Revista da Sociedade Brasileira de Medicina Tropical 1997;30:139-44.
7. Fabbro de Suasnábar D, Arias E, Streiger M, Piacenza M, Ingaramo M, Del Barco M, et al.Evolutive behavior towards cardiomyopathy of treated (nifurtimox or benznidazole) and untreated chronic chagasic patients. Revista de Instituto de Medicina Tropical de Sao Paulo 2000;42(2):99-109.
8. Gallerano R, Sosa R. Intervention study on the natural evolution of Chagas disease: evaluation of specific antiparasitic treatment [Estudio de intervencion en la evolucion natural de la enfermedad de Chagas: evaluacion del tratamiento antiparasitario especifico]. Revista de la Facultad de Ciencias Médicas (Córdoba, Argentina) 2000;57(2):135-62.
9. Galvão L, Chiari E, Macedo A, Luquetti A, Silva S, Andrade AL. PCR assay for monitoring Trypanosoma cruzi parasitemia in childhood after specific chemotherapy. Journal of Clinical Microbiology 2003;41(11):5066-70.
10. Gianella A, Holzman A, Lihoshi N, et al.Efficacy of allopurinol in chronic Chagas disease. Results of a randomized controlled trial in Santa Cruz, Bolivia [Eficacia del alopurinol en la enfermedad de Chagas crónica. Resultados del estudio realizado en Santa Cruz, Bolivia]. Boletín científico del CENETROP 1997;16:25-9.
11. Lauria-Pires L, Braga M, Vexenat A, Nitz N, Simões-Barbosa A, Tinoco D, et al.Progressive chronic chagas heart disease ten years after treatment with anti-Trypanosoma cruzi nitroderivatives. American Journal of Tropical Medicine and Hygiene 2000;63(3, 4):111-8.
12. Prado N, Hernández Y, De Rissio AM, Esteve M, Riarte A. Security in a randomized control trial (RCT) - TRAENA Study - in adult patients with Chagas disease [La seguridad en un ensayo clínico aleatorizado (ECA) - Estudio TRAENA - en pacientes adultos con Enfermedad de Chagas]. Instituto Nacional de Parasitología Dr M Fatala Chaben, ANLIS GCG Malbrán, Ministerio de Salud 2008.
13. Rassi A, Luquetti AO, Rassi A Jr, Rassi GG, Rassi SG, Da Silva IG, et al.Short report: specific treatment for Trypanosoma cruzi: lack of efficacy of allopurinol in the human chronic phase of Chagas disease. American Journal of Tropical Medicine and Hygiene 2007;76(1):58-61.
14. Silveira CAN. Avaliação a longo prazo do tratamento específico da doença de chagas [PhD thesis]. Distrito Federal, Brazil: Faculdade de Medicina, Universidade de Brasília, 2000:123pp.
15. Sosa-Estani S, Segura EL, Ruiz AM, Velazquez E, Porcel BM, Yampotis C. Efficacy of chemotherapy with benznidazole in children in the intermediate phase of Chagas' disease. American Journal of Tropical Medicine and Hygiene 1998;59:526-9.
16. Viotti R, Vigliano C, Bertocchi G, Petti M, Alvarez MG, Postan M, et al.Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment: a nonrandomized trial. Annals of Internal Medicine 2006;144(10):724-37.
17. Abitbol H. Treatment of Chagas disease [Tratamiento de la enfermedad de Chagas]. Anales de la Real Academia Nacional de Medicine (Madr) 1981;98:755-8.
18. Aguilera X, Apt W, Arribada A. [Evaluación del allopurinolen la enfermedad de Chagas crónica humana en Chile]. Parasitol Dia 1987;11:132-4.
19. Amato NV. Specific treatment of Chagas' disease [Tratamento específico da doença de Chagas]. Revista do Hospital das Clínicas 1980;35:27-34.
20. Amato NV. Therapeutics of the chronic form of Chagas' disease. Specific treatment of Trypanosoma cruzi infection [Terapêutica da forma crônica da doençade Chagas]. Arquivos Brasileiros de Cardiologia 1998;70:63-4.
21. Andrade SG, Macedo V. Combined treatment of Chagas' disease with Bayer 2502 and corticoid (experimental and clinical study) [Tratamento combinado dadoença de Chagas com Bayer 2502 e corticóide (Estudo experimental e clínico)]. Revista do Instituto de Medicina Tropical de Sao Paulo 1973;15:421-30.
22. Andrade SG, Rassi A, Magalhaes JB, Ferriolli FF, Luquetti AO. Specific chemotherapy of Chagas disease: a comparison between the response in patients and experimental animals inoculated with the same strains. Transactions of the Royal Society of Tropical Medicine and Hygiene 1992;86:624-6.
23. Apt W. Treatment of Chagas' disease [Tratamiento de la enfermedad de Chagas]. Revista Medica de Chile 1985;113:162-6.
24. Apt W, Aguilera X, Arribada A, Perez C, Miranda C, Zulantay I, et al.Treatment of chronic human Chagas disease with itraconazole and allopurinol. Preliminary report [Tratamiento de la enfermedad de Chagashumana con Itraconazol y alopurinol. Informe preliminar]. Revista Medica de Chile 1994;122:420-7.
25. Apt W, Arribada A, Zulantay I, Sanchez G, Vargas SL, Rodriguez J. Itraconazole or allopurinol in the treatment of chronic American trypanosomiasis: the regression and prevention of electrocardiographic abnormalities during 9 years of follow-up. Annals of Tropical Medicine and Parasitology 2003;97(1):23-9.
26. Apt W, Arribada A, Zulantay I, Solari A, Sanchez G, Mundaca K, et al.Itraconazole or allopurinol in the treatment of chronic American trypanosomiasis: the results of clinical and parasitological examinations 11 years post-treatment. Annals of Tropical Medicine and Parasitology 2005;99(8):733-41.
27. Bestetti RB. Should benznidazole be used in chronic Chagas' disease?. Lancet 1997;349:653.
28. Bocca Tourres CL. Acute period of Chagas' disease and its treatment with Bay 2502 [La enfermedad de Chagas en periodo agudo y su tratamiento con el Bay 2502]. Boletin Chilenocde Parasitologia 1969;24:24-7.
29. Braga S, Lauria-Pires L, Argañaraz E, Nascimento R, Teixeira A. Persistent infections in chronic Chagas' disease patients treated with anti-Trypanosoma cruzi nitroderivatives. Revista do Instituto de Medicina Tropical de Sao Paulo 2000;42(3):157-61.
30. Braga JCV, Reis F, Aras R, Costa ND, Bastos C, Silva R, et al.Clinical and therapeutic aspects of heart failure due to Chagas disease. Arquivos Brasileiros de Cardiologia 2006;86(4):296-301.
31. Brener Z. Chemotherapy of Trypanosoma cruzi infections. Advances in Pharmacological Chemotherapy 1975;13:1-81.
32. Cançado JR. Long term evaluation of etiological treatment of Chagas disease with benznidazole. Revista do Instituto de Medicina Tropical de Sao Paulo 2002;44(1):29-37.
33. Carpintero DJ. [Quimioterapia antiparasitaria en la tripanosomiasis americana (Enfermedad de Chagas). Relatode 15 años de experiencia]. CM Publicación Médica 1993;6:117-31.
34. Chippaux JP, Salas Clavijo A, Santalla J, Postigo J, Schneider D, Brutus L. Antibody drop in newborns congenitally infected by Trypanosoma cruzi treated with benznidazole. Tropical Medicine and International Health 2010;15(1):87-93.
35. Coura JR. Current prospects of specific treatment of Chagas' disease [Perspectivas actuales en el tratamiento específico de la enfermedad de Chagas]. Boletin Chileno de Parasitologia 1996;51:69-75.
36. Cutrullis R, Ballering G, Altcheh J, Moscatelli G, Corral R, Petray P, et al.Anti-M2 muscarinic receptor autoantibodies in Trypanosoma cruzi-infected pediatric patients treated with benznidazole. Revista de Patologia Tropical 2007;36(2):141-8.
37. De Araujo Malta J. [Terapêutica etiológica da doença de Chagas. Consensos e divergências]. Arquivos Brasileiros de Cardiologia 1993;61:201-2.
38. De Castro AM, Luquetti AO, Rassi A, Chiari E, Galvão LM. Detection of parasitemia profiles by blood culture after treatment of human chronic Trypanosoma cruzi infection. Parasitology Research 2006;99:379-83.
39. De Lana M, Lopes L, Martins H, Bahia M, Machado-de-Assis G, Wendling A, et al.Clinical and laboratory status of patients with chronic Chagas disease living in a vector-controlled area in Minas Gerais, Brazil, before and nine years after aetiological treatment. Memorias do Instituto Oswaldo Cruz 2009;104(8):1139-47.
40. De Oliveira H. [Tratamento da doença de Chagas (Fase aguda) com Bayer 2502]. Revista do Instituto de Medicina Tropical Sao Paulo 1967;9:343-5.
41. De Oliveira H. [Tratamento da forma indeterminada da doença de Chagas com Nifurtimox e Benznidazol]. Revista da Sociedade Brasileira de Medicina Tropical 1990;23:209-11.
42. Fabbro D, Streiger M, Arias E, Bizai M, Barco M, Amicone N. Trypanocide treatment among adults with chronic Chagas disease living in Santa Fe City (Argentina), over a mean follow-up of 21 years: parasitological, serological and clinical evolution [Tratamiento tripanocida em adultos chagasicos cronicos, residentes na cidade de Santa Fe (Argentina), com sequimento de 21 anos em media: evolucao parasitologica, sorolgica e clinica]. Revista da Sociedade Brasileira de Medicina Tropical 2007;40(1):1-10.
43. Fernandes C, Teicher F, Balbinot M, Liarte D, Scholl D, Steindel M, et al.Efficacy of benznidazol treatment for asymptomatic chagasic patients from state of Rio Grande do Sul evaluated during a three years follow-up. Memorias do Instituto Oswaldo Cruz 2009;104(1):27-32.
44. Fernandez JJ, Cedillos RA, Godoy GA. Treatment of acute Chagas' disease with Bay 2502 [Tratamiento de la enfermedad de Chagas crónica con Bay 2502]. Boletin Chileno de Parasitologia 1969;24:51-3.
45. Fragata Filho AA, da Silva MA, Boainain E. Ethiologic treatment of acute and chronic Chagas' disease. Revista Paulista de Medicina 1995;113:867-72.
46. Fragata-Filho AA, Boainaim E, Dias da Silva MA. Validade do tratamento etiológico na fase crônica da doença de Chagas com benznidazol. Arquivos Brasileiros de Cardiologia 1995;65(Suppl I):71.
47. Gallerano RH, Marr JJ, Sosa RR. Therapeutic efficacy of allopurinol in patients with chronic Chagas' disease. American Journal of Tropical Medicine and Hygiene 1990;43:159-66.
48. Gallerano RH, Sosa RR. [Allopurinol vs testigo en la parasitemia de la enfermedad de Chagas crónica asintomática valorada por xenodiagnósticos seriados]. Boletín Científico del CENETROP 1990;14:38-43.
49. Gonnert R. Nifurtimox: causal treatment of Chagas' disease. Arzneimittelforschung 1972;22:1563.
50. Gutteridge WE. Chemotherapy of Chagas' disease. Transactions of the Royal Society of Tropical Medicine and Hygiene 1976;70:123-4.
51. Ivanovic D. [Actualizacion sobre el tratamiento de la enfermedad de la enfermedad de Chagas]. Revista Chilena de Infectologia 1994;11:131-8.
52. Lacunza C, Negrete O, Mora M, Uncos A, Segura M, Castillo N, et al.Use of the polymerase chain reaction (PCR) for early evaluation of etiological treatment in young adults, chronically infected with Trypanosoma cruzi. Revista de Patologia Tropical 2006;35(3):227-32.
53. Levi GC, Amato NV. Treatment of patients with chronic Chagas' disease by means of the nitrofuran compound Bayer 2502 or Lampit [Observaçoes sôbre o tratamento de pacientes com a forma crônica da doença de Chagas mediante emprêgo do composto nitrofurânico "Bayer 2502" o "lampit"]. Revista do Instituto de Medicina Tropical de Sao Paulo 1971;13:369-72.
54. Levi GC, Lobo IM, Kallas EG, Amato Neto V. Etiological drug treatment of human infection by Trypanosoma cruzi. Revista do Instituto de Medicina Tropical de Sao Paulo 1996;38:35-8.
55. López-Antuñaño FJ. [Quimioterapia de las infecciones producidas por Trypanosoma cruzi]. Salud Pública de México 1997;39:463-71.
56. Maldonado M, Vera de Bilbao N, Samudio M, Schinini A, Acosta N, López E, et al.[Tratamiento con benznidazol en niños de seis a doce años infectados con T. cruzi]. EFACIM-EDUNA 1997:154-63.
57. Marr JJ, Docampo R. Chemotherapy for Chagas' disease: a perspective of current therapy and considerations for future research. Reviews of Infectious Diseases 1986;8:884-903.
58. Martins-Filho O, Eloi-Santos S, Carvalho A, Oliveira R, Rassi A, Luquetti O, et al.Double-blind study to evaluate flow cytometry analysis of anti-live Trypomastigote antibodies for monitoring treatment efficacy in cases of human Chagas' disease. Clinical and Diagnostic Laboratory Immunology 2002;9(5):1107-13.
59. Meirovich CI, Montrull HL, Gallerano RH, Sosa RR. Allopurinol in the treatment of chronic Chagas' disease [Allopurinol en el tratamiento de la enfermedad de Chagas crónica]. Arquivos Brasileiros de Cardiologia 1985;45:217-23.
60. Mendoza I, Guiniger A, Velazco V, Marques J, Moleiro F, Sgammini H. Opinion of the USCAS Electrophysiology Committee on the treatment of ventricular arrhythmias in Chagas disease [Opinión del Comité de Electrofisiología de USCAS sobre el tratamiento de las arritmias ventricularesen la enfermedad de Chagas]. Rev Urug Cardiol 1992;7:25-8.
61. Pérez-Molina J, Pérez-Ayala A, Morena S, Fernández-González C, Zamora J, López-Velez R. Use of benznidazole to treat chronic Chagas' disease: a systematic review with a meta-analysis. Journal of Antimicrobial Chemotherapy 2009;64:1139-47.
62. Prata A. Possibility of treatment in Chagas' disease [Possibilidade de tratamento na doença de Chagas]. Revista da Associacao Medica Brasileira (1992) 1978;24:140-2.
63. Rassi A. Etiological treatment of Chagas' disease [Tratamento etiológico da doença de Chagas]. Arquivos Brasileiros de Cardiologia 1982;38:277-81.
64. Romeu Cançado J, Salgado A, Cardoso dos Santos JF, Batista SM, Chiair CC. Clinical trials in Chagas' disease. New Approaches in American Trypanosomiasis Research. 1. Washington, DC: PAHO 1976:266-72.
65. Rubio M, Donoso F. Chagas' disease in children and its treatment with Bay 2502 [Enfermeda de Chagas en niños y tratamiento con Bay 2502]. Boletin Chileno de Parasitologia 1969;24:43-8.
66. Santana ET, Magalhaes J Jr, Nagashiro E, Nagashiro A, Sadae G, Delfino SA. [Doença de Chagas crônica. Situaçao actual de seu tratamento]. O Hospital 1969;76:67-75.
67. Silveira C, Castillo E, Castro C. Specific treatment evaluation for Trypanosoma cruzi in children in the evolution of the indeterminate phase [Avaliacão do tratamento específico para o Trypanosoma cruzi em criancas, naevolucão da fase indeterminada]. Revista da Sociedade Brasileira de Medicina Tropical 2000;33(2):191-6.
68. Sosa-Estani S, Armenti A, Araujo G, Viotti R, Lococo B, Ruiz Vera B, et al.Treatment of Chagas disease with benznidazole and thioctic acid [Tratamiento de la enfermedad de Chagas con benznidazol y acido tioctico]. MEDICINA (Buenos Aires) 2004;64:1-6.
69. Streiger M, Del Barco M, Fabbro D, Arias E, Amicone N. Longitudinal study and specific chemotherapy in children with chronic Chagas' disease, residing in a low endemicity area of Argentina [Estudo longitudinal e quimioterapia específica em criancas, com doenca de Chagas cronica, residentes em area de baixa endemicidade da republica Argentina]. Revista da Sociedade Brasieira de Medicina Tropical 2004;37(5):365-75.
70. Viotti R, Vigliano C, Armenti H, Segura E. Treatment of chronic Chagas' disease with benznidazole: clinical and serologic evolution of patients with long-term follow-up. American Heart Journal 1994;127:151-62.
71. Wegner DH, Rohwedder RW. The effect of nifurtimox in acute Chagas' infection. Arzneimittelforschung 1972;22:1624-35.
72. Wegner DH, Rohwedder RW. Experience with nifurtimox in chronic Chagas' infection. Preliminary report. Arzneimittelforschung 1972;22:1635-41.
73. Zulantay I, Arribada A, Honores P, Sánchez G, Solari A, Ortiz S, et al.No association between persistence of the parasite and electrocardiographic evolution in treated patients with Chagas disease [La mejoría electrocardiográfica con el tratamiento de la enfermedad de Chagas crónica, es independiente de la persistencia de Trypanosoma cruzi]. Revista Medica de Chile 2005;113:1153-60.
74. Marin-Neto JA, Rassi A Jr, Avezum A Jr, Mattos AC, Rassi A, Morillo CA, et al.The BENEFIT trial: testing the hypothesis that trypanocidal therapy is beneficial for patients with chronic Chagas heart disease. Memoria do Instituto Oswaldo Cruz 2009;104 Suppl 1:319-24.
75. Andrade SG, Freitas LAR, Peyrol S, Pimentel AR, Sadigursky M. Experimental chemotherapy of Trypanosoma cruzi infection: persistence of parasite antigens and positive serology in parasitologically cured mice. WHO Bulletin OMS 1991;69:191-7.
76. Apt W, Aguilera X, Arribada A, Perez C, Miranda C, Sanchez G, et al.Treatment of chronic Chagas' disease with itraconazole and allopurinol. American Journal of Tropical Medicine and Hygiene 1998;59(1):133-8.
77. Bahia MT, de Andrade IM, Martins TA, do Nascimento ÁF, Diniz L de F, Caldas IS, et al.Fexinidazole: a potential new drug candidate for Chagas disease. PLoS Neglected Tropical Diseases 2012;6(11):1-9.
78. Bern C, Montgomery SP, Herwaldt BL, Rassi A Jr, Marin-Neto JA, Dantas RO, et al.Evaluation and treatment of Chagas disease in the United States: a systematic review. JAMA 2007;298:2171-81.
79. Bern C, Montgomery SP. An estimate of the burden of Chagas disease in the United States. Clinical Infectious Diseases 2009;49(5):e52-4.
80. Chagas CA. [Ajente etiolojico de nova entidade morbida do homem]. Memorias do Instituto Oswaldo Cruz 1909;1(1):11-80.
81. Coura JR. Chagas disease: clinical and therapeutic features. Enfermedades Emergentes 2005;7:18-24.
82. Coura JR, Vinas PA. Chagas disease: a new worldwide challenge. Nature 2010;465:S6-7.
83. Dias JCP. Elimination of Chagas disease transmission: perspectives. Memorias do Instituto Oswaldo Cruz 2009;104:41-5.
84. Escriba JM, Ponce E, Romero Ade D, Vinas PA, Marchiol A, Bassets G, et al.Treatment and seroconversion in a cohort of children suffering from recent chronic Chagas infection in Yoro, Honduras. Memorias do Instituto Oswaldo Cruz 2009;104(7):986-91. [PUBMED: 20027465].
85. Follmann D, Elliott P, Suh I, Curter J. Variance imputation for overviews of clinical trials with continuous response. Journal of Clinical Epidemiology 1992;45:769-73.
86. Freitas HF, Chizzola PR, Paes AT, Lima AC, Mansur AJ. Risk stratification in a Brazilian hospital-based cohort of 1220 outpatients with heart failure: role of Chagas' heart disease. International Journal of Cardiology 2005;102(2):239-47.
87. Gallerano R, Sr. [Resultados de un estudio a largo plazo con drogas antiparasitarias en infectados chagásicos crónicos]. Revista de la Federación Argentina de Cardiología 2001;30:289-96.
88. Galvao LM, Chiari E, Macedo AM, Luquetti AO, Silva SA, Andrade AL. PCR assay for monitoring Trypanosoma cruzi parasitemia in childhood after specific chemotherapy. Journal of Clinical Microbiology 2003;41:5066-70.
89. García S, Ramos CO, Senra JF, Vilas-Boas F, Rodrigues MM, Campos de Carvalho AC, et al.Treatment with benznidazole during the chronic phase of experimental Chagas' disease decreases cardiac alterations. Antimicrobial Agents and Chemotherapy 2005;49(4):1521-8.
90. Grupo de trabajo científico OMS. [Reporte sobre la enfermedad de Chagas]. 2007; Vol. 17-20 de abril de 2005 (Actualizado en julio de 2007) - Buenos Aires Argentina.
91. Guhl F, Restrepo M, Angulo VM, Antunes CM, Campbell-Lendrum D, Davies CR. Lessons from a national survey of Chagas disease transmission risk in Colombia. Trends in Parasitology 2005;21(6):259-62.
92. Hagar JM, Rahimtoola SH. Chagas' heart disease in the United States. New England Journal of Medicine 1991;325(11):763-8.
93. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Intervention Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
94. Higuchi ML, Benvenuti LA, Martins RM, Metzger M. Pathophysiology of the heart in Chagas' disease: current status and new developments. Cardiovascular Research 2003;60(1):96-107.
95. Hotez PJ, Bottazzi ME, Franco-Paredes C, Ault SK, Periago MR. The neglected tropical diseases of Latin America and the Caribbean: a review of disease burden and distribution and a roadmap for control and elimination. PLoS Neglected Tropical Diseases 2008;2(9):e300.
96. Jones EM, Colley DG, Tostes S, Lopes ER, Vnencak-Jones CL, McCurley TL. Amplification of a Trypanosoma cruzi DNA sequence from inflammatory lesions in human chagasic cardiomyopathy. American Journal of Tropical Medicine and Hygiene 1993;48:348-57.
97. Kuschnir E, Sgammini H, Castro R, Evequoz C, Ledesma R, Brunetto J. Evaluation of cardiac function by radioisotopic angiography, in patients with chronic Chagas cardiopathy. Arquivos Brasileiros de Cardiologia 1985;45(4):249-56.
98. Laranja FS, Dias E, Nobrega G, Miranda A. Chagas' disease: a clinical, epidemiologic, and pathologic study. Circulation 1956;14(6):1035-60.
99. Lauria-Pires L, Braga MS, Vexenat AC, Nitz N, Simoes-Barbosa A, Tinoco DL, et al.Progressive chronic Chagas heart disease ten years after treatment with anti-Trypanosoma cruzi nitroderivatives. American Journal of Tropical Medicine and Hygiene 2000;63(3-4):111-8.
100. Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
101. López S, Risech E, Riarte A. [A nueve años de un estudio de tratamiento en adultos (TRAENA) con enfermedad de Chagas crónica: adherencia a los controles y expectativas de curación]. 2008.
102. Marinho CR, Imperio Lima MR, Grisotto MG, Alvarez JM. Influence of acute-phase parasite load on pathology, parasitism, and activation of the immune system at the late chronic phase of Chagas' disease. Infection and Immunity 1999;67(1):308-18.
103. Moncayo A. Chagas disease: current epidemiological trends after the interruption of vectorial and transfusional transmission in the Southern Cone countries. Memorios do Instituto Oswaldo Cruz 2003;98(5):577-91.
104. Perez-Molina JA, Perez-Ayala A, Moreno S, Fernandez-Gonzalez MC, Zamora J, Lopez-Velez R. Use of benznidazole to treat chronic Chagas' disease: a systematic review with a meta-analysis. Journal of Antimicrobial Chemotherapy 2009;64:1139-47.
105. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012.
106. Reyes PA, Vallejo M. Trypanocidal drugs for late stage, symptomatic Chagas disease (Trypanosoma cruzi infection). Cochrane Database of Systematic Reviews 2005, Issue 4. [DOI: 10.1002/14651858.CD004102.pub2].
107. Sosa ES, Segura EL. [Tratamiento de la infeccion por Trypanosoma cruzi en fase indeterminada. Experiencia y normatizacion actual en la Argentina]. Medicina 1999;59 Suppl 2:166-70.
108. Villar JC. Commentary: control of Chagas' disease: let's put people before vectors. International Journal of Epidemiology 2001;30(4):894-5.
109. WHO. Control of Chagas disease. Second Report of the WHO Expert Committee. Geneva: WHO, 2002.
110. WHO secretariat. Chagas disease: control and elimination: provisional agenda item 12.12 for the 62th World Health Assembly A62/17, 2009. apps.who.int/iris/bitstream/10665/2199/1/A62_17-en.pdf?ua=1 (accessed 8 May 2014).
111. WHO. Control and prevention of Chagas disease in Europe, 2010. www.fac.org.ar/1/comites/chagas/Chagas_WHO_Technical%20Report_16_06_10.pdf (accessed 8 May 2014).
112. Villar JC, Villar LA, Marin-Neto JA, Ebrahim S, Yusuf S. Trypanocidal drugs for chronic asymptomatic Trypanosoma cruzi infection. Cochrane Database of Systematic Reviews 2002, Issue 1. [: 10.1002/14651858.CD003463].